Axl receptor tyrosine kinase is a novel target of apigenin for the inhibition of cell proliferation

Kim,Kyung-Chan; Choi,Eun-Ha; Lee,Chuhee

doi:10.3892/ijmm.2014.1804

Axl receptor tyrosine kinase is a novel target of apigenin for the inhibition of cell proliferation

Authors:
- Kyung-Chan Kim
- Eun-Ha Choi
- Chuhee Lee
View Affiliations

Affiliations: Department of Internal Medicine, College of Medicine, Catholic University of Daegu, Daegu 705-718, Republic of Korea, Department of Biochemistry and Molecular Biology, School of Medicine, Yeungnam University, Daegu 705-717, Republic of Korea
Published online on: June 13, 2014 https://doi.org/10.3892/ijmm.2014.1804
Pages: 592-598

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Axl receptor tyrosine kinase (RTK), along with Tyro 3 and Mer, belongs to the TAM subfamily that promotes survival, stimulates proliferation and/or inhibits apoptosis. In various types of human cancer, including breast, lung and prostate cancer, Axl expression is increased and correlates with an advanced clinical stage. In this study, we examined whether apigenin has an effect on Axl expression, which in turn can affect cell proliferation. The treatment of the non‑small cell lung cancer (NSCLC) cells, A549 and H460, with apigenin decreased Axl mRNA and protein expression in a dose‑dependent manner. Axl promoter activity was also inhibited by apigenin, indicating that apigenin suppressed Axl expression at the transcriptional level. Upon treatment with apigenin, the viability of both the A549 and H460 cells was gradually decreased and the anti-proliferative effects were further confirmed by the dose‑dependent decrease in the clonogenic ability of the apigenin‑treated cells. Subsequently, we found that the viability and clonogenic ability of the cells treated with apigenin was less or more affected by transfection of the cells with a Axl-expressing plasmid or Axl targeting siRNA, compared to transfection with the empty vector or control siRNA, respectively. In addition, apigenin increased the expression of p21, a cyclin-dependent kinase inhibitor, but reduced the expression of X-linked inhibitor of apoptosis protein (XIAP). These cell cycle arrest and pro-apoptotic effects of apigenin were also attenuated or augmented by the up- or downregulation of Axl expression, respectively, which suggests that Axl is a novel target of apigenin through which it exerts its inhibitory effects on cell proliferation. Taken together, our data indicate that apigenin downregulates Axl expression, which subsequently results in the inhibition of NSCLC cell proliferation through the increase and decrease of p21 and XIAP expression, respectively.

View Figures

View References

1	Liu C, Tu FX and Chen X: Neuroprotective effects of apigenin on acute transient focal cerebral ischemia-reperfusion injury in rats. Zhong Yao Cai. 31:870–873. 2008.(In Chinese).
2	Svehliková V, Bennett RN, Mellon FA, et al: Isolation, identification and stability of acylated derivatives of apigenin 7-O-glucoside from chamomile (Chamomilla recutita [L.] Rauschert). Phytochemistry. 65:2323–2332. 2004.PubMed/NCBI
3	Birt DF, Hendrich S and Wang W: Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther. 90:157–177. 2001. View Article : Google Scholar : PubMed/NCBI
4	Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 3:768–780. 2003. View Article : Google Scholar : PubMed/NCBI
5	Manach C, Scalbert A, Morand C, Rémésy C and Jiménez L: Polyphenols: food sources and bioavailability. Am J Clin Nutr. 79:727–747. 2004.PubMed/NCBI
6	Yang CS, Landau JM, Huang MT and Newmark HL: Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr. 21:381–406. 2001. View Article : Google Scholar : PubMed/NCBI
7	Bevilacqua L, Buiarelli F, Coccioli F and Jasionowska R: Identification of compounds in wine by HPLC-tandem mass spectrometry. Ann Chim. 94:679–689. 2004. View Article : Google Scholar : PubMed/NCBI
8	Zheng PW, Chiang LC and Lin CC: Apigenin induced apoptosis through p53-dependent pathway in human cervical carcinoma cells. Life Sci. 76:1367–1379. 2005. View Article : Google Scholar : PubMed/NCBI
9	Lu HF, Chie YJ, Yang MS, et al: Apigenin induces apoptosis in human lung cancer H460 cells through caspase- and mitochondria-dependent pathways. Hum Exp Toxicol. 30:1053–1061. 2011. View Article : Google Scholar : PubMed/NCBI
10	Zhong Y, Krisanapun C, Lee SH, et al: Molecular targets of apigenin in colorectal cancer cells: involvement of p21, NAG-1 and p53. Eur J Cancer. 46:3365–3374. 2010. View Article : Google Scholar : PubMed/NCBI
11	Ruela-de-Sousa RR, Fuhler GM, Blom N, Ferreira CV, Aoyama H and Peppelenbosch MP: Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy. Cell Death Dis. 1:e192010. View Article : Google Scholar : PubMed/NCBI
12	Li ZD, Hu XW, Wang YT and Fang J: Apigenin inhibits proliferation of ovarian cancer A2780 cells through Id1. FEBS Lett. 583:1999–2003. 2009. View Article : Google Scholar : PubMed/NCBI
13	Shukla S, MacLennan GT, Flask CA, et al: Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res. 67:6925–6935. 2007. View Article : Google Scholar : PubMed/NCBI
14	Liu LZ, Fang J, Zhou Q, Hu X, Shi X and Jiang BH: Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol Pharmacol. 68:635–643. 2005.PubMed/NCBI
15	Fang J, Xia C, Cao Z, Zheng JZ, Reed E and Jiang BH: Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J. 19:342–353. 2005. View Article : Google Scholar : PubMed/NCBI
16	Mirzoeva S, Kim ND, Chiu K, Franzen CA, Bergan RC and Pelling JC: Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Mol Carcinog. 47:686–700. 2008. View Article : Google Scholar : PubMed/NCBI
17	Liu E, Hjelle B and Bishop JM: Transforming genes in chronic myelogenous leukemia. Proc Natl Acad Sci USA. 85:1952–1956. 1988. View Article : Google Scholar
18	O’Bryan JP, Frye RA, Cogswell PC, et al: axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 11:5016–5031. 1991.PubMed/NCBI
19	Rochlitz C, Lohri A, Bacchi M, et al: Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia. 13:1352–1358. 1999. View Article : Google Scholar : PubMed/NCBI
20	Berclaz G, Altermatt HJ, Rohrbach V, Kieffer I, Dreher E and Andres AC: Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast. Ann Oncol. 12:819–824. 2001. View Article : Google Scholar : PubMed/NCBI
21	Craven RJ, Xu LH, Weiner TM, et al: Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer. 60:791–797. 1995. View Article : Google Scholar : PubMed/NCBI
22	Ito T, Ito M, Naito S, et al: Expression of the Axl receptor tyrosine kinase in human thyroid carcinoma. Thyroid. 9:563–567. 1999. View Article : Google Scholar : PubMed/NCBI
23	Nemoto T, Ohashi K, Akashi T, Johnson JD and Hirokawa K: Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology. 65:195–203. 1997. View Article : Google Scholar : PubMed/NCBI
24	Shieh YS, Lai CY, Kao YR, et al: Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia. 7:1058–1064. 2005. View Article : Google Scholar : PubMed/NCBI
25	Hutterer M, Knyazev P, Abate A, et al: Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res. 14:130–138. 2008. View Article : Google Scholar : PubMed/NCBI
26	Sun WS, Fujimoto J and Tamaya T: Coexpression of growth arrest-specific gene 6 and receptor tyrosine kinases Axl and Sky in human uterine endometrial cancers. Ann Oncol. 14:898–906. 2003. View Article : Google Scholar
27	Gustafsson A, Martuszewska D, Johansson M, et al: Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res. 15:4742–4749. 2009. View Article : Google Scholar : PubMed/NCBI
28	Byers LA, Diao L, Wang J, et al: An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 19:279–290. 2013. View Article : Google Scholar : PubMed/NCBI
29	Liu L, Greger J, Shi H, et al: Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 69:6871–6878. 2009. View Article : Google Scholar : PubMed/NCBI
30	Holland SJ, Powell MJ, Franci C, et al: Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res. 65:9294–9303. 2005. View Article : Google Scholar : PubMed/NCBI
31	Giles KM, Kalinowski FC, Candy PA, et al: Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther. 12:2541–2558. 2013. View Article : Google Scholar : PubMed/NCBI
32	Birt DF, Walker B, Tibbels MG and Bresnick E: Anti-mutagenesis and anti-promotion by apigenin, robinetin and indole-3-carbinol. Carcinogenesis. 7:959–963. 1986. View Article : Google Scholar
33	Liang YC, Huang YT, Tsai SH, Lin-Shiau SY, Chen CF and Lin JK: Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis. 20:1945–1952. 1999. View Article : Google Scholar : PubMed/NCBI
34	Choi JS, Choi YJ, Park SH, Kang JS and Kang YH: Flavones mitigate tumor necrosis factor-alpha-induced adhesion molecule upregulation in cultured human endothelial cells: role of nuclear factor-kappa B. J Nutr. 134:1013–1019. 2004.
35	Plaumann B, Fritsche M, Rimpler H, Brandner G and Hess RD: Flavonoids activate wild-type p53. Oncogene. 13:1605–1614. 1996.PubMed/NCBI
36	Lepley DM and Pelling JC: Induction of p21/WAF1 and G1 cell-cycle arrest by the chemopreventive agent apigenin. Mol Carcinog. 19:74–82. 1997. View Article : Google Scholar : PubMed/NCBI
37	Shukla S and Gupta S: Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol Carcinog. 39:114–126. 2004. View Article : Google Scholar : PubMed/NCBI
38	Li Y, Ye X, Tan C, et al: Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene. 28:3442–3455. 2009. View Article : Google Scholar : PubMed/NCBI
39	Ye X, Li Y, Stawicki S, et al: An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene. 29:5254–5264. 2010. View Article : Google Scholar : PubMed/NCBI
40	Gusenbauer S, Vlaicu P and Ullrich A: HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene. 32:3846–3856. 2013. View Article : Google Scholar : PubMed/NCBI
41	Zhang Z, Lee JC, Lin L, et al: Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
42	Postel-Vinay S and Ashworth A: AXL and acquired resistance to EGFR inhibitors. Nat Genet. 44:835–836. 2012. View Article : Google Scholar : PubMed/NCBI
43	Dufies M, Jacquel A, Belhacene N, et al: Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Oncotarget. 2:874–885. 2011.PubMed/NCBI
44	Mahadevan D, Cooke L, Riley C, et al: A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene. 26:3909–3919. 2007. View Article : Google Scholar : PubMed/NCBI
45	Hong J and Belkhiri A: AXL mediates TRAIL resistance in esophageal adenocarcinoma. Neoplasia. 15:296–304. 2013.PubMed/NCBI